Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
This NIH/NINDS award (R61/R33) funds development of in vitro and ex vivo assays and screening to identify candidate therapeutics for neurological and neuromuscular disorders; no clinical trial is a…
- Deadline
- Oct 20, 2027
- Posted
- Oct 22, 2024
- Award amount
- Up to $750,000
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Oct 20, 2027 so you have time to apply.
In plain English
This NIH/NINDS award (R61/R33) funds development of in vitro and ex vivo assays and screening to identify candidate therapeutics for neurological and neuromuscular disorders; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $750,000. The early-stage drug-discovery focus makes the scope narrow.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this grant
This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · $50K–$600K · Due in 2 days
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
National Institutes of Health · $50K–$600K · Due in 2 days
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
National Institutes of Health · Up to $1.1M · Due in 27 days
NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
National Institutes of Health · Up to $750K · Due in 27 days
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
National Institutes of Health · Up to $1.5M · Due Jan 7, 2027
National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
National Institutes of Health · Up to $500K · Due Jan 7, 2027
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.